Cancer treatment in the STI571 era: what will change?

J Clin Oncol. 2001 Sep 15;19(18 Suppl):13S-16S.
No abstract available

MeSH terms

  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Drug Resistance, Neoplasm
  • Evidence-Based Medicine
  • Gastrointestinal Neoplasms / drug therapy*
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Neoplasm Recurrence, Local
  • Patient Selection
  • Piperazines / pharmacokinetics*
  • Piperazines / pharmacology*
  • Piperazines / therapeutic use
  • Pyrimidines / pharmacokinetics*
  • Pyrimidines / pharmacology*
  • Pyrimidines / therapeutic use
  • Stromal Cells / drug effects
  • Stromal Cells / pathology

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate